



I hereby certify that this correspondence is being deposited with the United States Postal Services on the date set forth below as First Class Mail in an envelope addressed to:
Commissioner for Patents, Washington, D.C. 20231.

Date of Signature
and Deposit:

7/26/01

Jean C. Baker

Attorney of Record

RECEIVED

AUG 02 2001

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Jeffrey Ross
Serial No.: 09/873,637
Filed: June 4, 2001
For: THE C-MYC CODING REGION DETERMINANT-
BINDING PROTEIN (CRD-BP) AND ITS
NUCLEIC ACID SEQUENCE
Group Art Unit: 1642
Examiner: --

Commissioner For Patents
Washington, D.C. 20231

STATEMENT UNDER 37 C.F.R. § 1.821(e)

Dear Sir:

The content of the attached Sequence Listing for the above-identified application, containing SEQ ID NOs: 1 - 46 is taken from parent application Serial No. 09/261,855, filed March 3, 1999. No new matter has been added.

Respectfully submitted,

Jeffrey Ross

July 26, 2001

By:

Jean C. Baker

Jean C. Baker
Registration No. 35,433
Attorney for Applicant
QUARLES & BRADY LLP
411 East Wisconsin Avenue
Milwaukee, WI 53202-4497
(414) 277-5709



SEQUENCE LISTING

<110> Ross, Jeffrey

<120> THE C-MYC CODING REGION DETERMINANT-BINDING PROTEIN
(CRD-BP) AND ITS NUCLEIC ACID SEQUENCE

<130> 960296.95131

<140>

<141>

<160> 46

<170> PatentIn Ver. 2.0

<210> 1

<211> 2224

<212> DNA

<213> Mus musculus

<400> 1

gggtggggtg sgtagaaagt ttgoggctcc cgccgcccgt atccacgcct atcggcatag 60
gaggatatcc gcccgcgccc gcccggatcg gcattgaatg gaacagtgtc cttgccccgc 120
cacggccacc atgaacaagc ttacatcgga caacctcaac gagagtgtga ccccgcgaga 180
cttgagaaaa gtattcgagg agcacaagat ctctacagc ggccagttct tggtaaatac 240
cggctacgcc ttctgtgatt gcccgacaga gcactgggag atgaaggcca tcgaaacttt 300
ctcggggaaa gtgaaactgc aaggaaaacg tctagagatt gaacactcag tccccaaaaa 360
acaaaggagt cgaaaaatac agatccgcaa tattccacct cagctccgat gggaagtgtc 420
agatagcctg ctggctcagt acggctacagt ggagaactgt gagcaagtga aactgaaag 480
tgagacagcg gtggtaaacg tcacctactc taaccgggag cagaccaggc aagctatcat 540
gaagctaaat ggccatcaac tggagaacca tgccctgaag gtctctaca tacctgatga 600
gcagataaca caaggtcctg agaatgggag tctgtgaggc tttgggtctc ggggcccagg 660
ccggcaaggg tcgcccgtgg cagcaggggc tccagccaag cagcagccag tggacatccc 720
tctccggctc ctgggtgccta cgcagtatgt aggcgctatc attggcaagg aggggtgccac 780
catccgaaac atcacaaaac agacgcagtc caaaatagac gtgcatagga aggagaatgc 840
gggcgctgag gagaaggcca tcagcgtgca ttcaaccctt gaaggctgct cctccgcgtg 900
caagatgata ttggagatta tgacaagga ggcaaaggac accaaaacgg cagatgaagt 960
tcccctgaag atcctggctc ataacaactt cgtcgggaga ctcataggca aggaaggccg 1020
gaacctgaag aagggtggagc aggacacaga gacgaagatc accatctcat cgctccagga 1080
cctcacgctc tataaccctg agaggaccat cactgtgaag ggccgcatg agaactgttg 1140
cagggccgag caggagatca tgaagaaagt tcgagaggct tacgagaacg acgtggccgc 1200
catgagcttg cagtcaccac tcatccctgg gcttaacctg gctgctgtag gtctcttccc 1260
agcttcatcc agcgctgtcc ctctctctcc cagcagtgct actggggctg ctccctatag 1320
ctccttcatg caggctccgg agcaggagat ggtacaagtg ttcattcccc cccaggctgt 1380
gggcgccatc attggcaaga agggccagca catcaacaa ctctcccgtt tcgccagcgc 1440
ctccatcaag attgtccac cagaaacacc tgactccaaa gttcgaatgg tcgtcatcac 1500
tggacccccca gaggtcagc tcaaggctca ggaagaatt tatggcaaac taaaagaaga 1560

RECEIVED

AUG 02 2001

TECH CENTER 1600/2900

093307 073007 093307 073007

Figure 1 consists of 12 bar charts, labeled (a) through (l), arranged in a grid. Each chart displays the percentage of total protein in various fractions (A, B, C, D, E, F, G, H, I, J, K, L) for different protein types (A, B, C, D, E, F, G, H, I, J, K, L) across different conditions (1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12). The charts are arranged in a grid, with each chart having its own y-axis scale and x-axis labels. The data is presented as a series of bars for each condition, with the height of the bar indicating the percentage of total protein in that fraction.

```

<400> 2
Met Asn Lys Leu Tyr Ile Gly Asn Leu Asn Glu Ser Val Thr Pro Ala
  1             5             10             15
Asp Leu Glu Lys Val Phe Ala Glu His Lys Ile Ser Tyr Ser Gly Gln
      20             25             30
Phe Leu Val Lys Ser Gly Tyr Ala Phe Val Asp Cys Pro Asp Glu His
      35             40             45
Trp Ala Met Lys Ala Ile Glu Thr Phe Ser Gly Lys Val Glu Leu Gln
      50             55             60
Gly Lys Arg Leu Glu Met Glu His Ser Val Pro Lys Lys Gln Arg Ser
  65             70             75             80
Arg Lys Ile Gln Ile Arg Asn Ile Pro Pro Gln Leu Arg Trp Glu Val
      85             90             95
Leu Asp Ser Leu Leu Ala Gln Tyr Gly Thr Val Glu Asn Cys Glu Gln
      100            105            110
Val Asn Thr Glu Ser Glu Thr Ala Val Val Asn Val Thr Tyr Ser Asn
      115            120            125
Arg Glu Gln Thr Arg Gln Ala Ile Met Lys Leu Asn Gly His Gln Leu
      130            135            140
Glu Asn His Ala Leu Lys Val Ser Tyr Ile Pro Asp Glu Gln Ile Thr
  145            150            155            160

```

Gln Gly Pro Glu Asn Gly Arg Arg Gly Gly Phe Gly Ser Arg Gly Gln
 165 170 175
 Pro Arg Gln Gly Ser Pro Val Ala Ala Gly Ala Pro Ala Lys Gln Gln
 180 185 190
 Pro Val Asp Ile Pro Leu Arg Leu Leu Val Pro Thr Gln Tyr Val Gly
 195 200 205
 Ala Ile Ile Gly Lys Glu Gly Ala Thr Ile Arg Asn Ile Thr Lys Gln
 210 215 220
 Thr Gln Ser Lys Ile Asp Val His Arg Lys Glu Asn Ala Gly Ala Ala
 225 230 235 240
 Glu Lys Ala Ile Ser Val His Ser Thr Pro Glu Gly Cys Ser Ser Ala
 245 250 255
 Cys Lys Met Ile Leu Glu Ile Met His Lys Glu Ala Lys Asp Thr Lys
 260 265 270
 Thr Ala Asp Glu Val Pro Leu Lys Ile Leu Ala His Asn Asn Phe Val
 275 280 285
 Gly Arg Leu Ile Gly Lys Glu Gly Arg Asn Leu Lys Lys Val Glu Gln
 290 295 300
 Asp Thr Glu Thr Lys Ile Thr Ile Ser Ser Leu Gln Asp Leu Thr Leu
 305 310 315 320
 Tyr Asn Pro Glu Arg Thr Ile Thr Val Lys Gly Ala Ile Glu Asn Cys
 325 330 335
 Cys Arg Ala Glu Gln Glu Ile Met Lys Lys Val Arg Glu Ala Tyr Glu
 340 345 350
 Asn Asp Val Ala Ala Met Ser Leu Gln Ser His Leu Ile Pro Gly Leu
 355 360 365
 Asn Leu Ala Ala Val Gly Leu Phe Pro Ala Ser Ser Ser Ala Val Pro
 370 375 380
 Pro Pro Pro Ser Ser Val Thr Gly Ala Ala Pro Tyr Ser Ser Phe Met
 385 390 395 400
 Gln Ala Pro Glu Gln Glu Met Val Gln Val Phe Ile Pro Ala Gln Ala
 405 410 415

<213> Homo sapiens

<400> 4

Gly Arg Arg Gly Leu Gly Gln Arg Gly Ser Ser Arg Gln Gly
1 5 10

<210> 5

<211> 14

<212> PRT

<213> Homo sapiens

<400> 5

Gly Arg Gly Gly Phe Asp Arg Met Pro Pro Gly Arg Gly Gly
1 5 10

<210> 6

<211> 13

<212> PRT

<213> Homo sapiens

<400> 6

Gly Arg Gly Gly Phe Gly Asp Arg Gly Gly Arg Gly Gly
1 5 10

<210> 7

<211> 14

<212> PRT

<213> Homo sapiens

<400> 7

Gly Arg Gly Gly Phe Gly Gly Arg Gly Gly Gly Arg Gly Gly
1 5 10

<210> 8

<211> 14

<212> PRT

<213> Homo sapiens

<400> 8

Leu Arg Arg Gly Asp Gly Arg Arg Arg Gly Gly Gly Arg Gly
1 5 10

<210> 9

<211> 13
 <212> PRT
 <213> Artificial Sequence

 <220>
 <223> Consensus sequence for SEQ ID NOs:3-8.

 <400> 9
 Gly Arg Gly Gly Phe Gly Arg Gly Gly Gly Arg Gly Gly
 1 5 10

<210> 10
 <211> 11
 <212> PRT
 <213> Mus musculus

<400> 10
 Gln Leu Arg Trp Glu Val Leu Asp Ser Leu Leu
 1 5 10

<210> 11
 <211> 11
 <212> PRT
 <213> Homo sapiens

<400> 11
 His Leu Gln Trp Glu Val Leu Asp Ser Leu Leu
 1 5 10

<210> 12
 <211> 10
 <212> PRT
 <213> Homo sapiens

<400> 12
 Gln Leu Arg Leu Glu Arg Leu Gln Ile Asp
 1 5 10

<210> 13
 <211> 11
 <212> PRT
 <213> Homo sapiens

<400> 13

Thr Ile Ser Ser Leu Gln Asp Leu Thr Leu Tyr
1 5 10

<210> 14
<211> 11
<212> PRT
<213> Homo sapiens

<400> 14
Thr Ile Ser Pro Leu Gln Glu Leu Thr Leu Tyr
1 5 10

<210> 15
<211> 11
<212> PRT
<213> Human immunodeficiency virus

<400> 15
Gln Leu Pro Pro Leu Glu Arg Leu Thr Leu Asp
1 5 10

<210> 16
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> Consensus sequence for SEQ ID NOs:10-15.

<400> 16
Gln Leu Leu Glu Leu Thr Leu
1 5

<210> 17
<211> 47
<212> PRT
<213> Mus musculus

<400> 17
Leu Leu Val Pro Thr Gln Tyr Val Gly Ala Ile Ile Gly Lys Glu Gly
1 5 10 15

Ala Thr Ile Arg Asn Ile Thr Lys Gln Thr Gln Ser Lys Ile Asp Val
20 25 30

<212> PRT
<213> Homo sapiens

<400> 23

Gln Phe Ile Pro Ala Leu Ser Val Gly Ala Ile Ile Gly Lys Gln Gly
1 5 10 15

Gln His Ile Lys Gln Leu Ser Arg Phe Ala Gly Ala Ser Ile Lys Ile
20 25 30

Ala Pro Ala Glu Ala Pro Asp Ala Lys Val Arg Met Val Ile Ile
35 40 45

<210> 24

<211> 48

<212> PRT

<213> Homo sapiens

<400> 24

Ile Arg Val Pro Ser Phe Ala Ala Gly Arg Val Ile Gly Lys Gly Gly
1 5 10 15

Lys Thr Val Asn Glu Leu Gln Asn Leu Ser Ser Ala Glu Val Val Val
20 25 30

Pro Arg Asp Gln Thr Pro Asp Glu Asn Asp Gln Val Val Val Lys Ile
35 40 45

<210> 25

<211> 50

<212> PRT

<213> Homo sapiens

<400> 25

Ile Leu Leu Gln Ser Lys Asn Ala Gly Ala Val Ile Gly Lys Gly Gly
1 5 10 15

Lys Asn Ile Lys Ala Leu Arg Thr Asp Tyr Asn Ala Ser Val Ser Val
20 25 30

Pro Asp Ser Ser Gly Pro Glu Arg Ile Leu Ser Ile Ser Ala Asp Ile
35 40 45

Glu Thr
50

<210> 26
<211> 47
<212> PRT
<213> Homo sapiens

<400> 26
Leu Leu Ile His Gln Ser Leu Ala Gly Gly Ile Ile Gly Val Lys Gly
1 5 10 15

Ala Lys Ile Lys Glu Leu Arg Glu Asn Thr Gln Thr Thr Ile Lys Leu
20 25 30

Phe Gln Glu Cys Cys Pro His Ser Thr Asp Arg Val Val Leu Ile
35 40 45

<210> 27
<211> 46
<212> PRT
<213> Homo sapiens

<400> 27
Val Thr Ile Pro Lys Asp Leu Ala Gly Ser Ile Ile Gly Lys Gly Gly
1 5 10 15

Gln Arg Ile Lys Gln Ile Arg His Glu Ser Gly Ala Ser Ile Lys Ile
20 25 30

Asp Glu Pro Leu Glu Gly Ser Glu Asp Arg Ile Ile Thr Ile
35 40 45

<210> 28
<211> 44
<212> PRT
<213> Homo sapiens

<400> 28
Phe Ile Val Arg Glu Asp Leu Met Gly Leu Ala Ile Gly Thr His Gly
1 5 10 15

Ala Asn Ile Gln Gln Ala Arg Lys Val Pro Gly Val Thr Ala Ile Asp
20 25 30

Leu Asp Glu Asp Thr Cys Thr Phe His Ile Tyr Gly
35 40

<210> 29
<211> 43
<212> PRT
<213> Homo sapiens

<400> 29
Ile Gln Val Pro Arg Asn Leu Val Gly Lys Val Ile Gly Lys Asn Gly
1 5 10 15

Lys Leu Ile Gln Glu Ile Val Asp Lys Ser Gly Val Val Arg Val Arg
20 25 30

Ile Glu Ala Glu Asn Glu Lys Asn Val Pro Gln
35 40

<210> 30
<211> 18
<212> PRT
<213> Artificial Sequence

<220>
<223> Consensus sequence for SEQ ID NOs:17-29.

<400> 30
Leu Leu Val Gly Leu Ile Gly Lys Gly Gly Leu Lys Leu Leu Leu Arg
1 5 10 15

Ile Ile

<210> 31
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide primer

<400> 31
gtbaaygary tbcaraa

<210> 32

17

<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide primer

<400> 32
ggvacvacva cytcdgc

17

<210> 33
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide primer

<400> 33
gctgccgtca aattctg

17

<210> 34
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide primer

<400> 34
tcgacggttt ccatatg

17

<210> 35
<211> 38
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide primer

<400> 35
aaccggctc gagcgccgc tttttttttt tttttttt

38

<210> 36
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide primer

<400> 36
acggcagctg aggtggtagt acc 23

<210> 37
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide primer

<400> 37
aaccgggctc gagcggccgc t 21

<210> 38
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide primer

<400> 38
aggttccgctc cttccttgcc aatg 24

<210> 39
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide primer

<400> 39
aacttcatct gccgttttgg 20

<210> 40
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide primer

<400> 40

catcaactgg agaaccatg

19

<210> 41

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide primer

<400> 41

gactgcgtct gttttgtgat g

21

<210> 42

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide primer

<400> 42

ctgtaggaga tcttgtgctc

20

<210> 43

<211> 32

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide primer

<400> 43

cgcaccgcca ccatggacaa gctttacatc gg

32

<210> 44

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide primer

<400> 44

actgggatct gacccatcct

20

<210> 45

<211> 16

<212> PRT
<213> Mus musculus

<220>
<221> PEPTIDE
<222> (8)
<223> Xaa where Xaa = Gln or Ile

<220>
<221> PEPTIDE
<222> (10)
<223> Xaa where Xaa = Lys or Arg

<220>
<221> PEPTIDE
<222> (11)
<223> Xaa where Xaa = Ile or Lys

<220>
<221> PEPTIDE
<222> (12)
<223> Xaa where Xaa = Tyr or Gly

<220>
<221> PEPTIDE
<222> (15)
<223> Xaa where Xaa = Ile or Leu

<400> 45
Pro Ala Gln Val Gly Ala Ile Xaa Gly Xaa Xaa Xaa Gln Xaa Xaa Lys
1 5 10 15

<210> 46
<211> 14
<212> PRT
<213> Mus musculus

<400> 46
Asn Glu Leu Gln Asn Leu Thr Ala Ala Glu Val Val Val Pro
1 5 10